Daily Focus: HGH Fragment 176-191 — The Lipolytic Tail With Beta-3 Receptor Dependence

The C-terminal fragment of human growth hormone, spanning residues 176 through 191, has long been promoted as a growth-free fat-loss peptide. Recent 2026 research summaries continue to reinforce the mechanism established in rodent work: the fragment stimulates triglyceride hydrolysis in adipose tissue while suppressing fatty-acid re-esterification, producing a 12 to 23 percent reduction in body fat in obese mouse models. Importantly, these effects are reported without the hyperglycemic or growth-promoting activity that complicates full-length growth hormone therapy.

A central mechanistic finding is the fragment's dependence on the beta-3 adrenergic receptor. Studies in beta-3 adrenergic receptor knockout mice show that the lipid-mobilizing effect disappears entirely, implicating a pathway involving diacylglycerol as a second messenger and hormone-sensitive lipase as the downstream effector. In isolated adipocytes, Fragment 176-191 stimulates lipolysis through this beta-3 pathway, suggesting its action is specifically tuned to fat cells rather than acting on classical growth hormone receptor signaling.

Despite thirty-plus years of research, no molecular receptor for the native fragment has been definitively identified, and there is still no published human pharmacokinetic data for the unmodified peptide. The only clinical signal comes from AOD-9604, a modified Fragment analog that advanced through Phase II obesity trials run by Metabolic Pharmaceuticals but ultimately failed to show meaningful weight loss at 300 micrograms twice daily in humans. That failure remains the most important data point for anyone considering the compound.

Fragment 176-191 is not FDA-approved for human use and remains a research compound. For users exploring its lipolytic effects, the honest summary is that the mechanistic story is compelling in rodents, the human translation has not materialized, and the compound continues to live or die on preclinical evidence alone.